Full Scientific Program : View or Download

8:10 AM

SESSION I. STATE OF THE ART IN PROSTATE CANCER CARE:

Current and Potential Impact of Precision Diagnostics on Precision Care

Moderators:

8:10 am

Screening

Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Department of Surgery

(Urology Service), Memorial Sloan Kettering Cancer Center and Associate Professor of

Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

8:25 am

Q & A

8:30 am

Keynote Address: Radiology Perspective and Radiomics

Hedvig Hricak, MD, PhD

8:45 am

Q & A

8:50 am

Urology Perspective on Baseline PSA and Early Detection of Prostate Cancer

Guidelines of the National Comprehensive Cancer Network (NCCN)

Adam Kibel, MD

9:05 am

Urology Perspective on Low-Risk Prostate Cancer – and the Emerging Impact of In Vitro Diagnostics,

In Vivo Imaging and Radiogenomics

Peter Pinto, MD, Head of Prostate Cancer Section, Urologic Oncology Branch, Center for Cancer

Research, National Cancer Institute, National Institutes of Health

9:20 am

Q & A

9:25 am

Radiation Oncology Perspective on High-Risk and Recurrent Prostate Cancer – and the Emerging Role

of Molecular Diagnostics, Imaging and Radiogenomics

Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller

School of Medicine

9:40 am

Keynote Address: Medical Oncology Perspective on Precision Diagnosis and Liquid Biopsy of

Advanced Prostate Cancer

David Nanus, MD, Mark W. Pasmantier Professor and Chief, Hematology and Oncology, New York-

Presbyterian, and Director of Genitourinary Oncology, Weill Cornell Medicine

9:55 am

Q & A

10:00 am

Coffee Break

10:20 am

Pathology Perspective

10;20 am

Anatomic Pathology:

Thomas Wheeler, MD, Chairman and Professor of Pathology, Baylor College of

Medicine

10:35 am

Molecular Pathology:

Angelo DeMarzo, MD, PhD, Associate Professor of Pathology, Urology, Oncology,

Johns Hopkins University School of Medicine

10:50 am

Q & A

10:55 AM

SESSION II. INCREASING BENEFITS AND REDUCING RISKS OF SCREENING WITH

NOVEL DIAGNOSTIC APPROACHES:

Improving Risk Assessment, Patient Selection for Biopsies and Tissue

Sampling Prior to Diagnosis of Prostate Cancer

10:55 am

Emerging Fluid-Based Molecular Diagnostics

Francesca Demichelis, PhD, Associate Professor and Head of Computational Oncology Laboratory,

Centre for Integrative Biology, University of Trento, Italy

11:10 am

Liquid Biopsies: Definition and Clinical Utility

Michael Donovan, MD, PhD, Professor of Pathology, Mount Sinai Medical Center

11:25 am

Q & A

11:30 am

Advanced Ultrasound

Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto,

Canada

11:45 am

Multi-Parametric MRI and Multi-Modality Image Fusion: Emerging Data and Role of PI-RADS

Peter Choyke, MD, Director, Molecular Imaging, Center for Cancer Research, National Cancer Institute,

National Institutes of Health

12:00 pm

Q & A

12:05 pm

In Vitro Diagnostics – and their Integration with In Vivo Imaging

Sanoj Punnen, MD, Assistant Professor of Surgery, University of Miami Miller School of Medicine

12:20 pm

Q & A

12:30 pm

Lunch Break

1:30 pm

Session II (Cont.) Panel on Risk Assessment Prior to Diagnosis of Prostate Cancer

Moderators, Speakers



Minhaj Siddiqui, MD, Assistant Professor of Surgery and Chief of Urologic Oncology,

University of Maryland



Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine;

and Member, NCCN Prostate Cancer Early Detection Panel



Stephen Zappala, MD, Assistant Clinical Professor of Urology, Tufts University School of

Medicine

2:00 PM

SESSION III. DIAGNOSTIC ASSESSMENT OF MEN WITH PROVEN PROSTATE CANCER:

2:00 pm

In Vivo Imaging and Radiomics

2:00 pm

Multi-Modality Imaging and Tumor Heterogeneity

Baris Turkbey, MD, Associate Research Physician, Molecular Imaging Program,

National Cancer Institute

2:15 pm

Molecular Imaging

Mehrdad Alemozaffar, MD, Assistant Professor of Urology, Emory University School

of Medicine

2:30 pm

Q & A

2:35 pm

Radiomics/Quantitative Imaging and Active Surveillance

Masoom Haider, MD, Professor and Radiologist-in-Chief, Sunnybrook Health

Sciences Center, University of Toronto, Canada

2:50 pm

Q & A

2:55 pm

Tissue-Based Genomics and Phenotypic Biomarkers

2:55 pm

Pathology Perspective

Angelo DeMarzo, MD, PhD

3:10 pm

Q & A

3:15 pm

Public Health Perspective

Jennifer Rider, ScD, MPH, Assistant Professor, Department of Epidemiology,

Boston University School of Public Health

3:30 pm

Q & A

3:35 pm

Urology Perspective: Live-Single-Cell Phenotypic Biomarkers and Precision

Oncology

David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and

Medical Director for Associated Medical Professionals

3:50 pm

Q & A

3:55 pm -

Coffee Break

4:15 pm

Radiogenomics: Emerging and Future Impact on Patient Evaluation, Treatment Selection and

Monitoring

4:15 pm

Immediate Treatment - Minhaj Siddiqui, MD

4:30 pm

Active Surveillance - Sanoj Punnen, MD

4:45 pm

Focal Treatment - Peter Pinto, MD

5:00 pm –

Panel on Diagnostic Evaluation of Men with Proven Prostate Cancer

6:00 pm

Speakers, Moderators, Panel Members and -



Nicolas Bloch, MD, Chief of MRI and Associate Professor of Radiology, Boston University

Medical Center;



Michael Donovan, MD;



Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital

and Professor of Radiology, Harvard Medical School;



Susan Noworolski, PhD, Associate Professor, Department of Radiology, UCSF; and



Amita Shukla-Dave, PhD, Deputy Service Chief for Predictive Informatics

and Director, Quantitative Imaging, Memorial Sloan Kettering Cancer Center



Srinivas Vourganti, MD, Urologic Oncologist and Assistant Professor, Rush University Medical

Center

7:00 pm -

Dinner Reception, Poster Competition and Industry Leadership Session on Innovation

9:30 pm

7:30 pm

David Gauden, PhD, Chief Scientific Officer, Blue Earth Diagnostics, United Kingdom

7:40 pm

Heinrich Von Busch, PhD, Product Owner, Artificial Intelligence for Oncology Imaging, Siemens

Healthineers, Germany

7:55 pm

Antoine Leroy, PhD, President, Koelis, France

8:00 pm

Brian Liu, PhD, Medical Science Liaison-Urology, Myriad, USA

8:05 pm

Randall Jones, D.E. (PhD, MBA), Founder and CEO, ScanMed, USA

8:10 pm

Jason Polzin, PhD, General Manager, GE MR Applications Segment

8:15 pm

Jerrold Wen, VP for Engineering, Exact Imaging, Canada

8:20 pm

Bela Denes, MD, Senior Director, Medical Affairs Urology, Genomic Health

8 AM

SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF FOCAL TREATMENT:

Patient Selection, Monitoring and Outcomes

8:00 am

Radiology Perspective: Precision Imaging and Focal Treatment

Clare Tempany, MD, Ferenc Jolesz MD Professor of Radiology, Harvard Medical School and Vice

Chair for Radiology Research, Brigham and Women’s Hospital

8:15 am

Q & A

8:20 am

Overview of Laser Treatment

Aytekin Oto, MD, MBA, Professor of Radiology and Surgery, Section Chief, Abdominal Imaging;

Director, Body MR Imaging, University of Chicago Medical Center

8:35 am

Overview of Cryoablation and Focused Ultrasound

Jurgen Futterer, MD, PhD, Interventional Radiologist, Nijmegen Medical Center and Professor,

University of Twente, The Netherlands

8:50: am

Q & A

8:55 AM

SESSION V: PRECISION ONCOLOGY AND ADVANCED PROSTATE CANCER

8:55 am

Overview

Wassim Abida, MD, PhD, Staff Oncologist, Memorial Sloan Kettering Cancer Center

9:10 am

Q & A

9:15 am

Germline Mutations and Germline Testing in Advanced Prostate Cancer

Peter Nelson, MD

9:30 am

Q & A

9:35 am

DNA Damage Repair and its Impact on Clinical Therapy

Michael Morris, MD

9:50 am

Q & A

9:55 am

Genomic Testing

Adam Feldman, MD, MPH, Assistant Professor and Director, Combined Harvard Urologic

Oncology Fellowship, Harvard Medical School and Assistant in Urology, Massachusetts General

Hospital

10:10 am

Q & A

10:15 am-

Coffee Break

10:35 am

10:35 am

Molecular Imaging, Nuclear Medicine and PET

10:35 am

Overview

Heather Jacene, MD, Assistant Professor of Radiology and Associate Program

Director, Brigham and Women's Joint Program in Nuclear Medicine, Harvard

Medical School

10:50 am

PSMA Imaging: Current and Potential Role in Patient Care

Steven Rowe, MD, PhD, Assistant Professor of Radiology, Johns Hopkins

University School of Medicine

11:05 am

Experience with PSMA PET at UCSF

Thomas Hope, MD, Assistant Professor in Residence in the Abdominal Imaging and

Nuclear Medicine, Department of Radiology, University of California, San Francisco

11:20 am

Q & A

11:25 am

Amino Acid Imaging for Recurrent Prostate Cancer

Ashesh B. Jani, MD, MSEE, Professor, Department of Radiation Oncology,

Emory University

11:40 am

Multi-Modality Imaging in Recurrent and Advanced Disease

Peter Choyke, MD

11:55 am

Q & A

12:30 – 1:15 PM

Lunch

1:15 pm – 2 pm

SUMMARY PANEL DISCUSSION:

Expediting Transfer of Promising Technologies from Laboratories to Clinics

Session Chairs:

Mark Buzza, PhD, MBA, Director, Global Biomedical Research Programs, Movember

Foundation, Australia and Faina Shtern, MD

1:15 pm

Perspective from Movember: Identifying and Filling Clinical Gaps and Needs

Mark Buzza, PhD, MBA

1:25 pm

Perspective from the USA Vice President Joe Biden’s Cancer Moonshot Initiative:

National Priorities and Infrastructure, Regularory and Reimbursement Policy

1:25 pm - Richard Frank, MD, Chief Medical Officer, Siemens Healthineers, USA

1:35 pm – Comments: Peter Choyke, MD and Minhaj Siddiqui, MD

1:40 pm

NCCN Clinical Guidelines for Early Detection of Prostate Cancer

Preston Sprenkle, MD

1:50 pm

Perspective from AdMeTech: Integration of Research, Medical Education, Public Awareness

and Advocacy for Changing Standards of Prostate Cancer Care

Faina Shtern, MD

2 PM

ADJOURN